Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma
From a research standpoint, extensive, strain-specific multicenter trials that include comprehensive product characterization, standardized outcome measures, and sufficient follow-up are essential to establish minimal effective doses, assess the durability of effects, and identify infrequent adverse events
J., Wice, B
The AMA 2025 Survey Data: What Prior Authorization Is Costing Physicians Right Now The AMA 2025 Prior Authorization Physician Survey, released May 13, 2026, surveyed physicians across all specialties
Radiant Results operates practices across multiple locations
Biochimica Biophysica Acta (BBA)-Bioenergetics 1767, 10731101